Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.

Individuals can access the conference call by dialing:

US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297

Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
Marissa Bych
ir@standardbio.com

Staff

Recent Posts

CelLBxHealth PLC Announces Preliminary Fourth Quarter 2025 Financial Results

GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

26 minutes ago

Disrupting Biotech: Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable

Jurek Kozyra, CEO of Nanovery, joins host Karla Jo Helms on the Disruption Interruption podcast…

9 hours ago

Disrupting Biotech: Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable

Jurek Kozyra, CEO of Nanovery, joins host Karla Jo Helms on the Disruption Interruption podcast…

9 hours ago

Relevant Health Helps Health Brands Reach New Heights

LOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- Relevant Health is a full-service growth partner built…

9 hours ago

Relevant Health Helps Health Brands Reach New Heights

LOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- Relevant Health is a full-service growth partner built…

9 hours ago

Children’s Brain Tumor Network to Empower National Expansion of Pediatric Data Sharing Through ARPA-H Pediatric Care eXpansion (PCX)

CBTN will help scale real-time, interoperable data across more than 200 hospitals nationwide.PHILADELPHIA, Jan. 15,…

9 hours ago